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CORRELATION BETWEEN TESTS OF
CELL-MEDIATED IMMUNITY
SIR There is much interest in the use of in vivo and in
vitro tests of immune competence in cancer patients. Some-
times only one of the many tests available is used, and fre-
quently the results have been related to prognosis.
We have compared the results of four tests of immune com-
petence in 58 women, 45 of whom had breast cancer. The
control group of 13 were age-matched with the cancer groups.
The four tests used were Mantoux and dinitrochlorobenzene
(D.N.C.B.) skin tests, lymphocyte stimulation by phytohaemagg-
lutinin (P.H.A.), and enumeration of T lymphocytes by means
of sheep red-blood-cell rosettes. The techniques are described
elsewhere.1-3
The results for each test were analysed by first defining
whether a patient had a good or a poor response to that test.
A patient was considered to have a poor response in the E-ro-
setting tests if her percentage T-lymphocyte count was more
than 2 standard deviations below the mean of the control
group. The response to P.H.A. stimulation was considered to be
poor if the level of response to a suboptimal concentration of
FREQUENCY OF POOR RESPONSES TO TESTS OF IMMUNE COMPETENCE
P.H.A. (0.3 &micro;g/m1) was less than 5000 disintegrations/min. Re-
sponses to D.N.C.B. and Mantoux skin testing were scored as
positive or negative.1
In the group studied different conclusions regarding the im-
mune competence of patients in different stages of breast
cancer might be drawn if the results of tests are considered in-
dividually (see table). The limited value of Mantoux skin test-
ing as a test of immune competence is emphasised by the fact
that 6/11 of the benign cases were negative.
Only 7 of the 42 patients with breast cancer had a good re-
sponse in all four tests. If the results of the Mantoux test were
excluded a good response to each of the remaining three tests
was found in 13/42 patients. The best concordance was in the
stage 3 patients where 7/8 patients had a good response in all
three tests. There were however, no significant positive corre-
lations between any of the tests. These findings suggest that
each test measures a different facet of immune responsiveness
or that the immune response is impaired in different ways in
each patient or that the tests are intrinsically unreliable.
We conclude that breast-cancer patients with stage-3 disease
are the most biologically homogeneous group (a conclusion
that we have reached previously from independent evidence3 1)
and that the information obtained from a single test of im-
mune function in a study of this kind is of limited value. It
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seems that when a tumour leads to immune depression then
the immune defect might be detected by any of the test sys-
tems. A defect was rarely detected in all tests, and this finding
argues strongly for a battery of tests to be done for each pa-
tient.
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SIR,&mdash;You state’ that, apart from the tropical splenomegaly
syndrome, Felty’s syndrome is the only other condition known
to be associated with a diffuse lymphocytic infiltration of the
hepatic sinuses. Although we have not seen this pattern of lym-
phoid infiltration of the liver in Felty’s syndrome we have seen
a severe infiltrate of lymphoid cells in the sinuses of the liver
in a number of conditions, including infectious mononucleosis
and hairy-cell leukaemia (leuk&aelig;mic reticuloendotheliosis).2-1
An identical pattern of hepatic sinusoidal infiltration may also
be seen in cases of malignant histiocytosis (histiocytic medull-
ary reticulosis). The cells in the sinuses in cases of infectious
mononucleosis and in hairy-cell leukaemia appear cytologically
benig, while the infiltrated histiocytic cells in malignant his-
tiocyiosis have malignant cytological features. The sinusoidal
infiltrates in all these disorders may be heavy despite the fact
that the number of these cells. in the peripheral blood may not
be increased or may even be low.
It is important for the pathologist to recognise that a
number of benign as well as malignant disorders may be as-
sociated with a similar pattern of hepatic infiltrate. The reason
for this pattern of infiltration in the liver is obscure.
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TRANSFER FACTOR IN MULTIPLE SCLEROSIS
SIR--Dr Poser (June 19, p. 1352) and Dr Fog and Dr
Duquette (July 10, p. 99) have commented on our trial6 of
transfer factor in multiple sclerosis; the points raised need
clarification. Dr Poser claims that, once the disease process
(i.e., plaque formation) is set in motion, it becomes irrever-
sible. This is pure speculation.
The duration of the trial was chosen because if transfer fac-
tor caused the arrest and elimination of the putative demye-
linating agent, it is most likely that some effect would have
been detected by the methods we used in examining our
patients. To be sure, one can never be certain that, if the trial
had continued for several years, an effect might not be
observed. This approach, whilst suitable for grantmanship,
does not in any way invalidate the design of this study.
The criticism that the doses of transfer factor were too small
seems unnecessary when, with each of the three injections, we
gave five times the concentration of transfer factor stated to
confer delayed hypersensitivity.
I would repeat, therefore, that further trials of transfer-fac-
tor therapy in multiple sclerosis are unwarranted until we
know more about the disease and about transfer factor itself.
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